A novel combination regimen of BET and FLT3 inhibition for FLT3-ITD acute myeloid leukemia
AUTHORS
Lee, et al
Programs
OPN-51107
https://doi.org/10.3324/haematol.2020.247346
Phase 1b Study of BET Inhibitor PLX2853 in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)
AUTHORS
Mims, et al
Programs
OPN-2853
Download PDF
BET inhibitors synergize with venetoclax to induce apoptosis in MYC-driven lymphomas with high BCL-2 expression
AUTHORS
Cummin, et al
Programs
OPN-2853 OPN-51107
https://doi.org/10.1182/bloodadvances.2020002231
Targeting BRD/BET proteins inhibits adaptive kinome upregulation and enhances the effects of BRAF/MEK inhibitors in melanoma
AUTHORS
Tiago, et al
Programs
OPN-51107
https://doi.org/10.1038/s41416-019-0724-y
Dose Escalation Study of BET Inhibitor PLX2853 in Patients with Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
AUTHORS
Pemmaraju, et al
Programs
OPN-2853
Download PDF
PLX3397 inhibits the accumulation of intra-tumoral macrophages and improves bromodomain and extra-terminal inhibitor efficacy in melanoma
AUTHORS
Erkes, et al
Programs
OPN-51107
https://doi.org/10.1111/pcmr.12845
Potentiated anti-tumor effects of BETi by MEKi in anaplastic thyroid cancer
AUTHORS
Zhu, et al
Programs
OPN-51107
https://doi.org/10.1530/ERC-19-0107
The next-generation BET inhibitor, PLX51107, delays melanoma growth in a CD8-mediated manner
AUTHORS
Erkes, et al
Programs
OPN-51107
https://doi.org/10.1111/pcmr.12788
Inhibition of NF-κB-Dependent Signaling Enhances Sensitivity and Overcomes Resistance to BET Inhibition in Uveal Melanoma
AUTHORS
Ambrosini, et al
Programs
OPN-51107
https://doi.org/10.1158/0008-5472.CAN-18-3177
Stromal fibroblast growth factor 2 reduces the efficacy of bromodomain inhibitors in uveal melanoma
AUTHORS
Chua, et al
Programs
OPN-51107
https://doi.org/10.15252/emmm.201809081